Literature DB >> 20959778

The effects of risedronate and exercise on osteoporotic lumbar rat vertebrae and their sensory innervation.

Sumihisa Orita1, Seiji Ohtori, Takana Koshi, Masaomi Yamashita, Kazuyo Yamauchi, Gen Inoue, Munetaka Suzuki, Yawara Eguchi, Hiroto Kamoda, Gen Arai, Tetsuhiro Ishikawa, Masayuki Miyagi, Nobuyasu Ochiai, Shunji Kishida, Masashi Takaso, Yasuchika Aoki, Tomoaki Toyone, Kazuhisa Takahashi.   

Abstract

STUDY
DESIGN: Investigation of sensory innervation of rat osteoporotic lumbar vertebrae using in vitro and in vivo models.
OBJECTIVE: To investigate (1) sensory innervation of osteoporotic rat vertebrae, (2) effects of risedronate on sensory neurons, (3) effects of osteoporosis treatment on bone mineral densities (BMDs) and the sensory innervation. SUMMARY OF BACKGROUND DATA: Osteoporotic patients without fractures sometimes experience vague low back pain of unknown origin. The mechanisms of osteoporosis treatments against the pain are unclear.
METHODS: (1) The expression of calcitonin gene-related peptide (CGRP) immunoreactive (-ir) or transient receptor potential vanilloid 1 (TRPV1)-ir nerve fibers in vertebrae and dorsal root ganglions (DRG) innervating L3 vertebrae of Sprague Dawley rats labeled with neurotracer were examined in control, sham, and ovariectomized (OVX) rats. (2) Cultured rat neonate DRG neurons in media containing different concentrations of risedronate were immunostained for CGRP, and we measured its activity using axonal length and proportion of CGRP-ir neurons. (3) BMDs and CGRP expression in DRG neurons innervating L3 vertebrae were examined in the following 5 groups: sham (treated with saline), OVX (saline), OVX+EXE (treadmill exercise), OVX+RIS (risedronate), and OVX+RIS+EXE (risedronate and exercise).
RESULTS: (1) A few CGRP-ir or TRPV1-ir nerve fibers were observed in the bone marrow. CGRP or TRPV1 expression in DRG was elevated in the OVX group (P < 0.05). (2) The axonal length and proportion of CGRP-ir neurons were dose-dependently suppressed (P < 0.05). (3) BMDs improved and the CGRP expression decreased in the risedronate-treated groups (P < 0.05), especially in the OVX+RIS+EXE group.
CONCLUSION: Sensory innervation of osteoporotic rat vertebrae showed increased expression of CGRP and TRPV1 in DRG neurons. Risedronate suppressed activity of CGRP-ir neurons in vitro, improved BMD, and decreased CGRP expression, especially together with exercise in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959778     DOI: 10.1097/BRS.0b013e3181d5959e

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  20 in total

1.  Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice.

Authors:  Yasuhisa Abe; Kousuke Iba; Koichi Sasaki; Hironori Chiba; Kumiko Kanaya; Tomoyuki Kawamata; Kimimitsu Oda; Norio Amizuka; Muneteru Sasaki; Toshihiko Yamashita
Journal:  J Bone Miner Metab       Date:  2014-03-16       Impact factor: 2.626

2.  Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis.

Authors:  J Iwamoto; K Makita; Y Sato; T Takeda; H Matsumoto
Journal:  Osteoporos Int       Date:  2010-11-23       Impact factor: 4.507

3.  The effect of teriparatide to alleviate pain and to prevent vertebral collapse after fresh osteoporotic vertebral fracture.

Authors:  Hiroyuki Tsuchie; Naohisa Miyakoshi; Yuji Kasukawa; Tomio Nishi; Hidekazu Abe; Toyohito Segawa; Yoichi Shimada
Journal:  J Bone Miner Metab       Date:  2015-03-14       Impact factor: 2.626

4.  Characterization of neuropathic component of back pain in patients with osteoporotic vertebral fractures.

Authors:  Antimo Moretti; Sara Liguori; Marco Paoletta; Giuseppe Toro; Milena Aulicino; Francesca Gimigliano; Giovanni Iolascon
Journal:  NeuroRehabilitation       Date:  2022       Impact factor: 1.986

5.  Bone mineral density is not associated with musculoskeletal pain in postmenopausal Korean women aged ≥50 years.

Authors:  Kyoung Min Lee; Chin Youb Chung; Soon-Sun Kwon; Tae Gyun Kim; In Hyeok Lee; Ki Jin Jung; Jin Woo Park; Sang Young Moon; Moon Seok Park
Journal:  Clin Rheumatol       Date:  2014-10-07       Impact factor: 2.980

6.  Eleven years of experience with bisphosphonate plus alfacalcidol treatment in a man with osteogenesis imperfecta type I.

Authors:  Jun Iwamoto; Yoshihiro Sato; Mitsuyoshi Uzawa; Hideo Matsumoto
Journal:  Ther Clin Risk Manag       Date:  2012-12-28       Impact factor: 2.423

7.  Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice.

Authors:  Toshihiro Sugiyama; Lee B Meakin; Gabriel L Galea; Brendan F Jackson; Lance E Lanyon; Frank H Ebetino; R Graham G Russell; Joanna S Price
Journal:  Bone       Date:  2011-04-09       Impact factor: 4.398

8.  Seven years' experience with etidronate in a woman with anorexia nervosa and vertebral fractures.

Authors:  Jun Iwamoto; Yoshihiro Sato; Mitsuyoshi Uzawa; Tsuyoshi Takeda; Hideo Matsumoto
Journal:  Ther Clin Risk Manag       Date:  2011-07-05       Impact factor: 2.423

9.  Transient receptor potential vanilloid 1-immunoreactive innervation increases in fractured rat femur.

Authors:  Yuya Kawarai; Miyako Suzuki; Kensuke Yoshino; Gen Inoue; Sumihisa Orita; Kazuyo Yamauchi; Yasuchika Aoki; Tetsuhiro Ishikawa; Masayuki Miyagi; Hiroto Kamoda; Go Kubota; Yoshihiro Sakuma; Yasuhiro Oikawa; Kazuhide Inage; Takeshi Sainoh; Jun Sato; Junichi Nakamura; Masashi Takaso; Tomoaki Toyone; Kazuhisa Takahashi; Seiji Ohtori
Journal:  Yonsei Med J       Date:  2014-01       Impact factor: 2.759

10.  Increase of TRPV1-immunoreactivity in dorsal root ganglia neurons innervating the femur in a rat model of osteoporosis.

Authors:  Kensuke Yoshino; Miyako Suzuki; Yuya Kawarai; Yoshihiro Sakuma; Gen Inoue; Sumihisa Orita; Kazuyo Yamauchi; Yasuchika Aoki; Tetsuhiro Ishikawa; Masayuki Miyagi; Hiroto Kamoda; Gou Kubota; Yasuhiro Oikawa; Kazuhide Inage; Takeshi Sainoh; Jun Sato; Junichi Nakamura; Tomoaki Toyone; Kazuhisa Takahashi; Seiji Ohtori
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.